Core Viewpoint - 卓正医疗 successfully raised a total of HKD 285 million through its IPO, with a net amount of HKD 209 million after deducting listing expenses. The opening price of the shares was HKD 81, reflecting a 37% increase from the issue price of HKD 59, leading to a market capitalization of HKD 5.2 billion [2][4]. Financial Performance - For the fiscal years 2022, 2023, and projected 2024, 卓正医疗 reported revenues of RMB 473.2 million, RMB 690.4 million, and RMB 958.6 million respectively. The gross profits for the same years were RMB 43.98 million, RMB 133.5 million, and RMB 226 million [5][6]. - The company experienced operating losses of RMB 137.6 million in 2022, RMB 66.9 million in 2023, and a projected loss of RMB 46.9 million in 2024. However, it is expected to turn a profit of RMB 80.2 million in 2024 [6][7]. Shareholder Structure - Major cornerstone investors in 卓正医疗 include Health Vision, 金域医学检验, 明略科技, and Galaxy Dynasty, with total subscriptions amounting to HKD 90.8 million. Health Vision contributed HKD 44 million, while Galaxy Dynasty, associated with 小鹏汽车's CEO, invested USD 1 million [3]. - Post-IPO, the shareholding structure shows Cheuk Sing Ho holding 17.52%, Tencent holding 14.73%, and H Capital holding 11.31% among other investors [14]. Business Model and Expansion - 卓正医疗, founded in 2012, operates nearly 30 physical locations across major Chinese cities, providing a wide range of medical services including internal medicine, surgery, pediatrics, and aesthetic medicine [5]. - The company has expanded its portfolio by acquiring a 51.04% stake in 武汉神龙天下, which includes a children's hospital and two clinics in Wuhan [5]. Market Position - The company’s market capitalization reached HKD 5.2 billion shortly after its IPO, indicating strong investor interest and confidence in its growth potential [4].

Core Viewpoint -卓正医疗控股有限公司 is preparing for an IPO on the Hong Kong Stock Exchange after passing the listing hearing, showcasing significant revenue growth and strategic acquisitions in the healthcare sector [2][3]. Financial Performance - For the first eight months of 2025, 卓正医疗 reported revenue of 696.67 million RMB, up from 615.04 million RMB in the same period last year, representing a growth of approximately 13.5% [4][5]. - The gross profit for the same period was 167.27 million RMB, compared to 152.42 million RMB in the previous year, indicating an increase of about 9.7% [4][5]. - Operating profit turned positive at 12.73 million RMB, a significant improvement from an operating loss of 29.89 million RMB in the prior year [4][5]. - The net profit for the first eight months of 2025 was 83.21 million RMB, compared to 52.16 million RMB in the same period last year, marking a year-on-year increase of approximately 59.7% [4][5]. Business Model and Services - 卓正医疗, founded in 2012 in Shenzhen, operates nearly 30 physical locations across major Chinese cities, offering integrated online and offline healthcare services [3]. - The company provides a wide range of medical services, including internal medicine, surgery, obstetrics and gynecology, pediatrics, dentistry, dermatology, aesthetic medicine, ophthalmology, ENT, personalized health check-ups, day surgeries, air transfers, and international referrals [3]. Strategic Acquisitions - In early 2024, 卓正医疗 acquired a 51.04% stake in 武汉神龙天下, which includes the Wuhan Beidouxing Children's Hospital and two clinics, enhancing its service offerings and market presence [3]. Historical Financing and Valuation - 卓正医疗 has undergone multiple financing rounds, with the most recent being a $60 million investment in August 2021, leading to a post-money valuation of $510 million [7][8]. - The company has seen its valuation increase from $146 million in 2017 to $510 million in 2021, reflecting strong investor confidence and growth potential [7][8]. Shareholding Structure - Major shareholders include Tencent with a 19.39% stake and H Capital with 14.89%, indicating significant backing from prominent investment firms [9][11].

Core Viewpoint - Kangji Medical Holdings Limited plans to initiate a privatization delisting process with an overall valuation of approximately HKD 11.2 billion [2] Group 1: Privatization Details - The privatization is initiated by a consortium led by founder Zhong Ming, along with Shentu Yinguang, global private equity giant TPG, TPG's NewQuest V Fund, and Qatar Investment Authority's Al-Rayyan Holding [5] - The proposed share cancellation price is HKD 9.25 per share, representing a 21.7% premium over the closing price of HKD 7.6 on June 30, 2025, and exceeding the highest closing price of HKD 8.66 since 2022 [5] - Upon completion of the transaction, Kangji Medical will become a wholly-owned subsidiary of the offeror and will delist from the Hong Kong Stock Exchange [5] Group 2: Financial and Ownership Structure - The offeror consortium currently holds 74.75% of Kangji Medical's shares and has received irrevocable support commitments from some institutional shareholders [6] - After privatization, Zhong Ming and his wife will hold 40% of the ultimate holding company (TopCo) through Fortune Spring ZM and Fortune Spring YG, maintaining their position as the largest shareholders [6] - The funding for the transaction includes HKD 2.08 billion in equity financing and external debt financing, with a total cash consideration of approximately HKD 5.818 billion [6] Group 3: Company Background and Performance - Kangji Medical was established in 2004 and raised HKD 3.6 billion when it listed on the Hong Kong Stock Exchange in 2020, becoming one of the largest healthcare IPOs that year [6] - The company's products cover multiple departments, including obstetrics and gynecology and general surgery, serving over 3,500 hospitals in more than 90 countries and regions, including over 1,000 top-tier hospitals [6] - In 2024, Kangji Medical reported revenue of HKD 1.008 billion and a net profit of HKD 581 million, achieving double growth for five consecutive years, although the growth rate fell below 10% for the first time due to centralized procurement policies [6]